Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

NIH investigates next-generation cancer immunotherapeutic

April 14, 1999

Preliminary analysis of Biomira's synthetic cancer vaccine

April 13, 1999

Onyvax awarded grant for cancer vaccines

April 13, 1999

Preclinical and clinical results with Virulizin in pancreatic cancer presented at AACR meeting

April 12, 1999

LeukoSite and Ilex hold pre-BLA meeting with FDA

April 12, 1999

GVAX prostate cancer vaccine enters additional phase I/II trial

April 9, 1999

NeoPharm to collaborate with NCI on cytotoxic cancer ligand

April 9, 1999

Progress with AltaRex's AIT products for cancer

April 8, 1999

M-Vax cancer vaccine granted orphan drug designation

April 6, 1999

Antisoma's Theragyn granted orphan drug status in the U.S.

April 6, 1999

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...